NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co.
KgaA, and Merz Pharmaceuticals GmbH announced that they have filed a second
lawsuit in the U.S. District Court for the District of Delaware against
additional companies for infringement of U.S. Patent No. 5,061,703 (the
'703 patent), which relates to Forest's Namenda(R) product. The defendants
named in the lawsuit include Dr. Reddy's Laboratories Limited, Genpharm
Inc., Interpharm Inc., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories
Limited, Sun India Pharmaceutical Industries Limited, and related companies
and subsidiaries thereof. The '703 patent expires in April 2010. Forest has
applied for patent term extension which, if granted, would extend the '703
patent until September 2013.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
As previously reported, Forest and Merz had received notification from
several companies that they had filed Abbreviated New Drug Applications
with Paragraph IV certifications to obtain approval to market generic
versions of Namenda and commenced an action in patent infringement in the
U.S. District Court in Delaware against such filers.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
each of Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President - Investor
Relations, Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
